Effect of Health Status and Heat-Induced Inactivation on the Proteomic Profile of Plasma Rich in Growth Factors Obtained from Donors with Chronic Inflammatory Skin Conditions.

atopic dermatitis lichen sclerosus platelet-rich plasma proteome psoriasis skin inflammation thermal inactivation

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
26 Jun 2024
Historique:
received: 20 05 2024
revised: 16 06 2024
accepted: 21 06 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

Atopic dermatitis, psoriasis and lichen sclerosus are among the most challenging conditions treated by dermatologists worldwide, with potentially significant physical, social and psychological impacts. Emerging evidence suggests that autologous-platelet-rich plasma could be used to manage skin inflammation. However, the presence of soluble autoimmune components could hinder their therapeutic potential. The aim of this study was to analyze the proteomic profile of plasma rich in growth factors (PRGFs) obtained from donors with inflammatory skin conditions to evaluate the impact of skin health status on the composition and bioactivity of PRGF-based treatments. Venous blood from healthy volunteers and patients with psoriasis, lichen sclerosus and atopic dermatitis was processed to produce PRGF supernatant. Half of the samples were subjected to an additional thermal treatment (56 °C) to inactivate inflammatory and immune molecules. Proteomic analysis was performed to assess the protein profile of PRGFs from healthy and non-healthy patients and the effect of Immunosafe treatment. Differential abundance patterns of several proteins related to key biological processes have been identified, including complement activation, blood coagulation, and glycolysis- and gluconeogenesis-related genes. These results also demonstrate that the thermal treatment (Immunosafe) contributes to the inactivation of the complement system and, as a consequence, reduction in the immunogenic potential of PRGF products.

Identifiants

pubmed: 39062477
pii: biom14070763
doi: 10.3390/biom14070763
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Basque Country Government (Spain)
ID : KK-2020/00015

Auteurs

Eduardo Anitua (E)

University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01007 Vitoria, Spain.
BTI-Biotechnology Institute, 01005 Vitoria, Spain.

Roberto Tierno (R)

University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01007 Vitoria, Spain.
BTI-Biotechnology Institute, 01005 Vitoria, Spain.

Mikel Azkargorta (M)

Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, 48160 Derio, Spain.

Félix Elortza (F)

Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, 48160 Derio, Spain.

Mohammad H Alkhraisat (MH)

University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01007 Vitoria, Spain.
BTI-Biotechnology Institute, 01005 Vitoria, Spain.

Classifications MeSH